We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Endometrial Priming for Embryo Transfer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01430650
First Posted: September 8, 2011
Last Update Posted: September 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Miguel Angel Checa, Parc de Salut Mar
June 20, 2011
September 8, 2011
September 20, 2017
July 2010
October 2014   (Final data collection date for primary outcome measure)
Difference between day means in endometrial priming to achieve 7 mm. [ Time Frame: 11-16 days ]
Same as current
Complete list of historical versions of study NCT01430650 on ClinicalTrials.gov Archive Site
  • Biochemical Pregnancy rate [ Time Frame: 26-30 days ]
    To calculate the biochemical pregnancy rate, we will divide the number of biochemical pregnancy into the number of embryonary transference and multiply by 100.
  • The patient's adherence to the recommended treatment. [ Time Frame: 1-16 days ]
  • Biochemical Pregnancy rate [ Time Frame: 26-30 days ]
    To calculate the biochemical pregnancy rate, we will divide the number of biochemical pregnancy into the number of embrionary transference and multiply by 100.
  • The patient's adherence to the recommended treatment. [ Time Frame: 1-16 days ]
Not Provided
Not Provided
 
Endometrial Priming for Embryo Transfer
A Randomised Control Trial to Evaluate Efficacy and Safety of Two Different Protocols of Endometrial Priming for Embryo Transfer.

The aim of this trial is compare two different endometrial priming protocols

  • women that receive oral estrogens
  • women that receive transdermal estrogens
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Sterility
  • Drug: Oral strogen
    2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.
  • Drug: Transdermal strogen
    One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.
  • Experimental: Oral strogen
    Intervention: Drug: Oral strogen
  • Experimental: Transdermal strogen
    Intervention: Drug: Transdermal strogen
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
140
July 2015
October 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women between 18-50 years old with desire of children and needs of embryo transfer.
  • Plasma prolactin less than 30.
  • Uterine cavity that allow pregnancy, body mass index between 20-30.
  • And signed consent inform.

Exclusion Criteria:

  • History of estrogen dependent cancer, unknown origin vaginal bleeding.
  • Ovarian cyst.
  • Contraindications to be pregnant.
  • Estrogen allergy.
Sexes Eligible for Study: Female
18 Years to 50 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT01430650
UREP-PREPENDO-2010
No
Not Provided
Not Provided
Miguel Angel Checa, Parc de Salut Mar
Parc de Salut Mar
Not Provided
Not Provided
Parc de Salut Mar
September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP